Core Viewpoint - Harvard Bioscience, Inc. announced the resignation of Chief Financial Officer Jennifer Cote, effective upon the filing of the Quarterly Report on Form 10-Q, expected by May 12, 2025. Mark Frost has been appointed as the Interim CFO and Treasurer following her departure [1]. Group 1: Management Changes - Jennifer Cote's resignation will take effect upon the filing of the Company's Quarterly Report on Form 10-Q, anticipated by May 12, 2025 [1]. - Mark Frost has been appointed as the Interim Chief Financial Officer and Treasurer effective upon Ms. Cote's resignation [1]. - Mark Frost brings over 30 years of financial and executive-level management experience, having served as CFO for multiple public healthcare companies and as a consultant to Harvard Bioscience since January 2025 [2]. Group 2: Leadership Statements - Jim Green, Chairman and CEO, expressed confidence in Mark Frost's financial and business acumen, highlighting his extensive experience in corporate finance and as a public company CFO [3]. - Green acknowledged Jennifer Cote's contributions to the company, particularly in leading the finance team and driving initiatives such as the ERP system consolidation project [3]. Group 3: Company Overview - Harvard Bioscience, Inc. is a leading developer, manufacturer, and seller of technologies and services that support advances in life science applications, including research and drug discovery [4]. - The company serves a diverse customer base, including academic institutions, government laboratories, and leading pharmaceutical and biotechnology organizations globally [4].
Harvard Bioscience Announces CFO Transition